STACIA GOLLIHAR: Open Payments
NPI 1265741508 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,012 in 47 payments from 29 companies in 2025. Trend: 2023 $133 · 2024 $847 · 2025 $1,012
Food & beverage: $1,012
| Company | Payments | Amount |
|---|---|---|
| Exelixis Inc. | 4 | $93 |
| Novartis Pharmaceuticals Corporation | 4 | $91 |
| Gilead Sciences, Inc. | 3 | $86 |
| Janssen Biotech, Inc. | 2 | $60 |
| ABBVIE INC. | 2 | $51 |
| Kite Pharma, Inc. | 2 | $50 |
| Eisai Inc. | 2 | $42 |
| BeiGene USA, Inc. | 2 | $40 |
| TerSera Therapeutics LLC | 2 | $40 |
| Celgene Corporation | 2 | $38 |
Products named: CABOMETYX, Trodelvy, TEVIMBRA, PLUVICTO, Yescarta, Lenvima, Zoladex, REBLOZYL.
Industry payments across TX — which companies pay providers there.
